COGT · NASDAQ · Biotechnology

Cogent Biosciences

Develops bezuclastinib and other mutation-targeted therapies for mast-cell disease and cancer.

$34.59
After-hours close−0.08 (−0.24%)
At close$34.67(−6.52%)
DateEstimateReportedSurprise
Nov 2026−$0.57
Aug 2026−$0.55−$0.52+6.3%
May 2026−$0.53−$0.530.0%
Feb 2026−$0.51−$0.55−7.8%
Nov 2025−$0.54−$0.50+7.4%

The latest year is open to everyone — the 36 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Nov 2019
Aug 2019
May 2019
Mar 2019
Nov 2018
Aug 2018
May 2018
Mar 2018
Dec 2017
Jun 2017
Mar 2017
Sep 2016
Sep 2015
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 6, 2026−$0.57$750.0K
Aug 10, 2026−$0.55−$0.52+6.3%$1.0K
May 5, 2026−$0.53−$0.530.0%$500
Feb 17, 2026−$0.51−$0.55−7.8%$1.7M
Nov 7, 2025−$0.54−$0.50+7.4%

The latest year is open to everyone — the 36 quarters behind it read with an account.

Sign in
Aug 5, 2025
May 6, 2025
Feb 25, 2025
Nov 12, 2024
Aug 6, 2024
May 7, 2024
Feb 26, 2024
Nov 2, 2023
Aug 8, 2023
May 9, 2023
Mar 14, 2023
Nov 14, 2022
Aug 9, 2022
May 10, 2022
Mar 15, 2022
Nov 10, 2021
Aug 16, 2021
May 12, 2021
Mar 16, 2021
Nov 9, 2020
Aug 11, 2020
May 11, 2020
Mar 26, 2020
Nov 12, 2019
Aug 12, 2019
May 13, 2019
Mar 28, 2019
Nov 12, 2018
Aug 13, 2018
May 14, 2018
Mar 29, 2018
Dec 31, 2017
Jun 30, 2017
Mar 31, 2017
Sep 30, 2016
Sep 30, 2015